Vergelijking

Eloralintide vs. Maridebart Cafraglutide

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Metabool

CAS-nr.

geen gegevens

Molecuulmassa

geen gegevens

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Eloralintide

Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.

Maridebart Cafraglutide

MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Eloralintide	Maridebart Cafraglutide
Duitsland	Niet goedgekeurd	Niet goedgekeurd
Verenigde Staten	Niet goedgekeurd	Niet goedgekeurd

Volledige vermeldingen

Eloralintide

Volledige vermelding →

Maridebart Cafraglutide

Volledige vermelding →

Frequently asked questions

What is the difference between Eloralintide and Maridebart Cafraglutide?: Eloralintide is classified as "Metabool", while Maridebart Cafraglutide is classified as "Metabool". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Eloralintide or Maridebart Cafraglutide?: The highest available evidence level is "Humane RCT" for Eloralintide and "Humane RCT" for Maridebart Cafraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Eloralintide and Maridebart Cafraglutide in Germany and the United States?: Duitsland: Eloralintide — Niet goedgekeurd, Maridebart Cafraglutide — Niet goedgekeurd. Verenigde Staten: Eloralintide — Niet goedgekeurd, Maridebart Cafraglutide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.

Country

Eloralintide

Maridebart Cafraglutide

Duitsland

Niet goedgekeurd

Verenigde Staten

Niet goedgekeurd

Frequently asked questions

What is the difference between Eloralintide and Maridebart Cafraglutide?

Eloralintide is classified as "Metabool", while Maridebart Cafraglutide is classified as "Metabool". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Eloralintide or Maridebart Cafraglutide?

The highest available evidence level is "Humane RCT" for Eloralintide and "Humane RCT" for Maridebart Cafraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Eloralintide and Maridebart Cafraglutide in Germany and the United States?

Duitsland: Eloralintide — Niet goedgekeurd, Maridebart Cafraglutide — Niet goedgekeurd. Verenigde Staten: Eloralintide — Niet goedgekeurd, Maridebart Cafraglutide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.